Empowered Funds’s Recursion Pharmaceuticals RXRX Stock Holding History

Empowered Funds’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,098	Closed	-$53.6K	–	2192
2025 Q4	$53.6K	Buy	13,098 +132	+1%	+$654	﹤0.01%	985
2025 Q3	$63.3K	Buy	12,966 +1,624	+14%	+$8.53K	﹤0.01%	1802
2025 Q2	$57.4K	Buy	11,342 +1,293	+13%	+$6.35K	﹤0.01%	1735
2025 Q1	$53.2K	Buy	+10,049	New	+$73.3K	﹤0.01%	1605

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Empowered Funds's RXRX Position: Q1 2026 in Review

Empowered Funds sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 13,098 shares — an estimated $53.6K sold.

Empowered Funds first reported a position in RXRX in Q1 2025 and held it in 4 quarters. The position peaked at $63.3K in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Empowered Funds reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Empowered Funds sold 13,098 Recursion Pharmaceuticals shares in Q1 2026, an estimated $53.6K.
Empowered Funds first reported a position in Recursion Pharmaceuticals in Q1 2025 and held it in 4 quarters.
Empowered Funds's Recursion Pharmaceuticals position peaked at $63.3K in Q3 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Empowered Funds's 13F filing for Q1 2026, filed 15 May 2026.